PhaseBio Pharmaceuticals Stock (NASDAQ: PHAS)
|Day Range0.8 - 0.87||52 Wk Range0.5 - 2.7||Open / Close0.8 / -||Float / Outstanding40.5M / 49.9M|
|Vol / Avg.27K / 244.6K||Mkt Cap43.1M||P/E-||50d Avg. Price1.1|
|Div / Yield-||Payout Ratio-||Total Float40.5M||EPS-0.34|
|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of PhaseBio Pharmaceuticals (NASDAQ: PHAS) through any online brokerage.
The latest price target for PhaseBio Pharmaceuticals (NASDAQ: PHAS) was reported by Needham on Monday, August 15, 2022. The analyst firm set a price target for 8.00 expecting PHAS to rise to within 12 months (a possible 825.50% upside). 2 analyst firms have reported ratings in the last year.
The stock price for PhaseBio Pharmaceuticals (NASDAQ: PHAS) is $0.8644 last updated Today at September 27, 2022, 2:01 PM UTC.
There are no upcoming dividends for PhaseBio Pharmaceuticals.
PhaseBio Pharmaceuticals’s Q3 earnings are confirmed for Wednesday, November 9, 2022.
There is no upcoming split for PhaseBio Pharmaceuticals.
PhaseBio Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.